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Abstract: There is an urgent need to develop new antibiotics against multidrug-resistant bacteria.
Many antimicrobial peptides (AMPs) are active against such bacteria and often act by destabilizing
membranes, a mechanism that can also be used to permeabilize bacteria to other antibiotics, resulting in
synergistic effects. We recently showed that G3KL, an AMP with a multibranched dendritic topology of
the peptide chain, permeabilizes the inner and outer membranes of Gram-negative bacteria including
multidrug-resistant strains, leading to efficient bacterial killing. Here, we show that permeabilization
of the outer and inner membranes of Pseudomonas aeruginosa by G3KL, initially detected using the
DNA-binding fluorogenic dye propidium iodide (PI), also leads to a synergistic effect between
G3KL and PI in this bacterium. We also identify a synergistic effect between G3KL and six different
antibiotics against the Gram-negative Klebsiella pneumoniae, against which G3KL is inactive.
Keywords: antimicrobial peptides; dendrimers; membrane permeabilization; antibiotics; synergy
1. Introduction
There is an urgent need to develop new antibiotics due to the increasing resistance of bacteria to the
current antibiotics. Antibiotic resistance is particularly problematic with Gram-negative bacteria due
to the presence of an additional outer membrane, which, in combination with multidrug efflux pumps,
represents an efficient barrier against most antimicrobial compounds [1]. Many antimicrobial peptides
(AMPs) show strong activities against multidrug-resistant Gram-negative bacteria [2–9]. Most AMPs
act by directly disrupting the bacterial outer membrane and sometimes the inner membrane, and have
therefore been investigated as permeabilizing agents for other antibiotics. These are typically antibiotics
that act on intracellular targets on Gram-positive bacteria but are inactive on Gram-negative bacteria
due to lack of cell penetration, leading to synergistic effects [10–30].
Herein, we report our investigation of possible synergistic effects between antibiotics and peptide
dendrimer G3KL as a membrane permeabilizing agent (Figure 1). G3KL is an antimicrobial peptide
dendrimer discovered by optimizing an initial combinatorial library hit [31] by sequence design,
and exhibiting remarkable activity against Gram-negative bacteria such as Pseudomonas aeruginosa,
Acinetobacter baumannii, and Escherichia coli including multidrug-resistant clinical isolates, but no
activity against Klebsiella pneumoniae or methicillin-resistant Staphylococcus aureus (MRSA) [32,33].
G3KL selectively disrupts bacterial versus mammalian membrane models as evidenced by vesicle
leakage assays [32], displaying pro-angiogenic properties in biological burn-wound bandages [34],
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anti-biofilm activity [35,36], low toxicity to mammalian cells (IC50 ~1000µg/mL) [37], and low propensity
to resistance development [38]. Our study was motivated by our recent observation that G3KL acts
as a rapid membrane permeabilizer and strong membrane disruptor of bacterial cells. In this study,
we show that G3KL destabilizes the LPS (lipopolysaccharide) layer, disrupts the outer and the inner
membranes, interacts with DNA, and accumulates in Gram-negative bacteria up to an amount of
dendrimer corresponding to 10% of the bacterial weight [37].
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2. Results and Discussion
2.1. Membrane Permeabilization and Synergy with Propidium Iodide
We previously showed that G3KL permeabilizes the outer and inner membranes of P. aeruginosa
cells using fluorescence microscopy and propidium iodide (PI), a fluorogenic DNA-binding dye,
which is impermeable to intact cell membranes [37]. Permeabilization of bacterial membranes by
G3KL might enable entry of potent antibacterial compounds at sub-inhibitory concentrations of
G3KL and the cytotoxic compound. To test the feasibility of this approach and possible synergy
between antimicrobials and G3KL, we used the classical checkerboard assay and stained live bacteria
with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) (Figure 2) [32,39,40]. Synergy is
a positive interaction in which the effect of the combined drugs is greater than when they are
used alone. An additive effect indicates that the effects of the drugs used together are the same as
when used independently. An indifferent effect is observed when the combination of the drugs is as
efficient as the most potent drug alone. Antagonism is a negative effect observed when the combined
effect of the drugs is significantly less than expected [41,42]. Interpretation of the fractional inhibitory
concentration index (FICi) was followed as described by Park et al. [43]. We considered a synergistic
effect for FICi < 0.5; partial synergy for 0.5 ≤ FICi < 1; additive for FICi = 1; indifferent for 1 < FICi < 4;
antagonism for FICi ≥ 4.Molecules 2020, 25, x FOR PEER REVIEW 4 of 12 
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We investigated P. aeruginosa, A. baumannii, E. coli, and K. pneumoniae as Gram-negative bacteria
and MRSA as Gram-positive bacterium. We first tested whether the permeabilization effect of
G3KL observed with PI might result in a synergistic effect with this dye, which binds to DNA and
therefore should interfere with bacterial growth [44]. When used alone, PI was essentially inactive
against Gram-negative bacteria but showed moderate activity against MRSA (methicillin-resistant
Staphylococcus aureus) (Table 1). In the checkerboard assay, we observed a partial synergistic effect
with G3KL in P. aeruginosa (FICi = 0.5, Figure 2A), in line with our previous microscopy studies [37].
Partial synergy also occurred with E. coli (FICi = 0.6, Figure S1) and A. baumannii (FICi < 0.53, Figure S2).
These data suggest that G3KL permeabilizes the bacterial membranes below its MIC value to facilitate
the entry of PI.











G3KL a 4 4 8 >64 >64
PI a ≥500 62.5–250 >500 ≥500 62.5
PMB a 0.25 0.25 0.125 0.125 64
G3KLcomb/PIcomb (FICi) b 2/8 (0.5) 2/31.3 (0.6) 4/15.6 (<0.53) >64/>500 (-) >64/62.5 (>2)
PMBcomb/PIcomb (FICi) b 0.125/62.5 (0.6) 0.125/31.25 (0.6) 0.063/125 (<0.8) 2/16 (>4) 16/31.25 (0.8)
a Minimal inhibitory concentration (MIC) values in µg/mL were determined by serial 12 dilution in MHB
(Mueller-Hinton broth). b MIC in combination in µg/mL was determined by checkerboard method. FICi
was calculated as the sum of FIC of drug A (FIC A) and FIC of drug B (FIC B): FICA(MICAcomb/MICA) +
FICB(MICBcomb/MICB) = ΣFIC = FICindex (FICi). Interpretation of FICi was as follows: synergistic effect for FICi < 0.5;
partial synergy for 0.5 ≤ FICi < 1; additive for FICi = 1; indifferent for 1 < FICi < 4; antagonism for FICi ≥ 4 [43].
In the cases where no discrete MIC value was determined in the checkerboard assay, FIC values were calculated by
using the highest dilution used in the assay.
In the case of K. pneumoniae, neither PI nor G3KL nor their combination showed any activity
(Figure S3). As G3KL permeabilizes K. pneumoniae toward other antibiotics (see below), we interpret
these data as an indication that PI is inactive against this bacterium at the highest concentration used,
even in the presence of membrane permeabilization. The effect between PI and G3KL was indifferent
in the case of MRSA, indicating that G3KL, which is inactive against this bacterium, also does not
significantly increase the activity of PI against this bacterium (Figure S4).
By comparison, polymyxin B (PMB), a well-known membrane-disrupting natural antimicrobial
cyclic peptide [45,46], showed partial synergistic effects with PI in P. aeruginosa (FICi = 0.6, Figure S5),
E. coli (FICi = 0.6, Figure S1), A. baumannii (FICi < 0.8, Figure S2), and MRSA (FICi = 0.8, Figure S4),
but showed a surprising antagonistic effect in the case of K. pneumoniae (FICi > 4, Figure S3), which is
difficult to rationalize as PMB is known to permeabilize this bacterium [45].
2.2. G3KL Synergizes with Small Molecule Antibiotics against K. pneumoniae
We next conducted a broader survey to test if membrane permeabilization by G3KL might
enable synergistic effects with classical antibiotics using the checkerboard assay with P. aeruginosa
and K. pneumoniae as Gram-negative bacteria and MRSA as Gram-positive bacterium. We tested
vancomycin [47], erythromycin [48], and trimethoprim [49], which are active against Gram-positive
bacteria but inactive against Gram-negative bacteria due to inefficient uptake. We also tested
novobiocin, which is most active against Gram-positive bacteria but shows activity against some
Gram-negative pathogenic strains [50,51], as well as the broad-spectrum antibiotics ciprofloxacin [52],
chloramphenicol [53], gentamicin [54], azithromycin [55], sulfamethoxazole, and ampicillin [56].
In P. aeruginosa, the combination of G3KL with ampicillin did not lead to synergy (Figure S6),
as expected, due to the presence of the AmpC β-lactamase and the MexAB-OprM efflux pump
in this bacterium [57]. We observed partial synergy of G3KL in combination with vancomycin
(FICi = 0.6), chloramphenicol (FICi = 0.6), and azithromycin (FICi = 0.5), in line with the partial
synergy observed with PI (Figures S6 and S7). Combination of G3KL with erythromycin or
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sulfamethoxazole led to an additive effect (FICi = 1, Figure S7), indicating that, in both cases, G3KL
and the antibiotic act independently on their target without interfering with each other. An indifferent
effect was observed between G3KL and novobiocin, ciprofloxacin, gentamicin, and trimethoprim
(Figures S8 and S9). In general, the absence of synergy reflects that the concentration of G3KL
necessary for membrane permeabilization (1–2 µg/mL) is very close to its MIC value when used alone
(4–8 µg/mL). Nevertheless, G3KL was shown to kill P. aeruginosa within two hours by disrupting the
outer membrane, the inner membrane, and ultimately by complexing with some negatively charged
intracellular components, which probably includes DNA and proteins [37]. Thus, it is possible that
G3KL impairs the binding of small molecule drugs to such targets, which would also contribute to the
absence of synergistic effects.
In the case of K. pneumoniae, we observed a strong synergy between G3KL and vancomycin
(FICi < 0.3, Figure 2B), erythromycin (FICi < 0.3), novobiocin (FICi < 0.2), chloramphenicol (FICi < 0.5),
azithromycin (FICi < 0.4), and trimethoprim (FICi < 0.5), and partial synergy with the broad-spectrum
antibiotic gentamicin (FICi < 0.6) (Figures S10 and S11, Table 2). The synergistic effects between G3KL
and vancomycin, erythromycin, or trimethoprim are particularly striking because these compounds
were inactive against K. pneumoniae when used alone. These synergistic effects suggest that G3KL was
able to permeabilize K. pneumoniae cells even if it was not active against the bacterium, in line with
that close derivatives of G3KL showing significant activity against K. pneumoniae [58–60]. Synergies
have been reported previously between polymyxin B/colistin and small molecule antibiotics in
K. pneumoniae [10–14,30,61]. Synergistic effects involving a permeabilizing but inactive compound
have been previously observed with polymyxin B nonapeptide (PMBN), an inactive polymyxin B
derivative lacking the fatty acyl chain [11,62].







G3KL 4–8 >64 >64
Vancomycin 256 256 0.5
G3KLcomb/Vancomycincomb (FICi) b 1/32 (0.6) 16/16 (<0.3) >64/0.5 (>2)
Erythromycin 128 64 0.5
G3KLcomb/Erythromycincomb (FICi) b 2/64 (1) 8/8 (<0.3) 32/0.25 (<1)
Ampicillin >256 >256 128
G3KLcomb/Ampicillincomb (FICi) b 4/>256 (>2) >64/>256 (-) 32/64 (<1)
Novobiocin >256 16 0.31
G3KLcomb/Novobiocincomb (FICi) b 2/256 (<1.5) 8/1 (<0.2) >64/0.31 (>2)
Ciprofloxacin 0.125 0.031 0.25
G3KLcomb/Ciprofloxacincomb (FICi) b 4/0.125 (2) >32/0.031 (>2) >64/0.25 (>2)
Chloramphenicol 8 8 8
G3KLcomb/Chloramphenicolcomb (FICi) b 2/1 (0.6) 16/2 (<0.5) >64/8 (>2)
Gentamicin 1 2 0.5
G3KLcomb/Gentamicincomb (FICi) b 4/1 (2) 32/0.25 (<0.6) 64/0.25 (<1.3)
Azithromycin 64 4 4
G3KLcomb/Azithromycincomb (FICi) b 8/0.5 (0.5) 8/1 (<0.4) 16/2 (<0.8)
Sulfamethoxazole 256 >256 >32
G3KLcomb/Sulfamethoxazolecomb (FICi) b 1/128 (1) >64/>256 (-) >64/>32 (-)
Trimethoprim 128 >256 >32
G3KLcomb/Trimethoprimcomb (FICi) b 4/128 (2) 32/8 (<0.5) 64/32 (<1.5)
a The minimal inhibitory concentration in µg/mL was determined by two-fold serial dilutions in MH medium.
The experiments were performed in triplicate and the values in µg/mL were calculated based on the peptide mass
without trifluoroacetate counterions. b MIC in combination (G3KL/antibiotics) in µg/mL were determined by the
checkerboard method. The FICi in brackets was calculated as the sum of FIC of drug A (FIC A) and FIC of drug B
(FIC B): FICi was calculated as the sum of FIC of drug A (FIC A) and FIC of drug B (FIC B). FICA(MICAcomb/MICA)
+ FICB(MICBcomb/MICB) = ΣFIC = FICindex (FICi). Interpretation of FICi as follows: synergistic effect for FICi < 0.5;
partial synergy for 0.5 ≤ FICi < 1; additive for FICi = 1; indifferent for 1 < FICi < 4; antagonism for FICi ≥ 4 [43].
In the cases where no discrete MIC value was determined in the checkerboard assay, FIC values were calculated by
using the highest dilution used in the assay.
G3KL did not increase the activity of ampicillin and sulfamethoxazole, which were inactive against
K. pneumoniae when used alone (Figure S12). In the case of ampicillin, the antibiotic is probably degraded
by the naturally-occurring β-lactamase in K. pneumoniae NCTC 418, rendering permeabilization
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inefficient [63]. G3KL also did not significantly increase the activity of ciprofloxacin, which is very
active and whose activity is not limited by uptake (Figure S12).
Finally, we tested the permeabilization effect of G3KL in a Gram-positive MRSA strain. The results
showed a very weak permeabilization effect, in line with G3KL being inactive against this bacterium.
We observed a weak synergy between G3KL with erythromycin (FICi < 1), ampicillin (FICi < 1),
and azithromycin (FICi < 0.8) (Figure S13) and an indifferent effect with all the other antibiotics
(Figures S14–S16), suggesting that G3KL is unable to pass the peptidoglycan layer and reach the
membrane, and therefore cannot permeabilize MRSA for the uptake of small molecule drugs.
To confirm the synergistic effect observed in the checkerboard assay, we performed
time-kill experiments for the combinations of G3KL with vancomycin (FICi < 0.3), erythromycin
(FICi < 0.3), novobiocin (FICi < 0.2), and trimethoprim (FICi < 0.5). Killing kinetics on
K. pneumoniae at an initial inoculum of ~106 CFU/mL showed that the pairs G3KL/vancomycin
(32 µg/mL/32 µg/mL) and G3KL/trimethoprim (32 µg/mL/16 µg/mL) effectively killed the bacteria after
4 h, and G3KL/erythromycin (32 µg/mL/16 µg/mL) after 8 h, all below the MIC level (Figure 3). The pair
G3KL/novobiocin did not show a reduction in bacterial burden but exhibited a growth-inhibiting
activity. The low level of surviving bacteria might not have been detected in the checkerboard assay.
Similar growth inhibition was observed for novobiocin when used alone at 2 ×MIC (16 µg/mL) against
K. pneumoniae (Figure 3 and Figure S17). This effect was also observed in previous studies against E. coli,
which suggested that novobiocin generally inhibits cell division and induces slower cell growth [50,64].
Note that G3KL, vancomycin, trimethoprim, erythromycin, and novobiocin when used alone at the
same concentration as in combination showed no effect on bacterial killing.
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Figure 3. Static time-kill assay with G3KL, the antibiotics vancomycin, erythromycin, and novobiocin,
and their combination with G3KL. The experiment showed a decline in K. pneumoniae bacterial
burden at 37 ◦C for the combination of G3KL/vancomycin (32 µg/mL/32 µg/mL), G3KL/erythromycin
(32 µg/mL/16 µg/mL), and G3KL/trimethoprim (32 µg/mL/16 µg/mL) below the MIC level.
The combination G3KL/novobiocin (32 µg/mL/2 µg/mL) showed inhibition in K. pneumoniae growth.
The assays were performed in triplicate.
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3. Materials and Methods
3.1. Compounds
Peptide dendrimer G3KL was synthesized by solid-phase peptide synthesis and purified
as described earlier [32]. Vancomycin, ampicillin, novobiocin, azithromycin, sulfamethoxazole,
and trimethoprim were purchased from Sigma Aldrich (Buchs, Switzerland), erythromycin
and ciprofloxacin were purchased from Acros Organics (Geel, Belgium), and chloramphenicol
and gentamicin were purchased from AppliChem (Darmstadt, Germany). All compounds
were conditioned as 8 or 10 mg/mL stock solutions in water (G3KL, ampicillin,
novobiocin, chloramphenicol, and gentamicin), 1% acetic acid (ciprofloxacin), and DMSO
(erythromycin, azithromycin, sulfamethoxazole, and trimethoprim).
3.2. Broth Microdilution Method
Antimicrobial activity was assayed against P. aeruginosa (PAO1), A. baumannii (ATCC19606), E. coli
W3110 (TE823), K. pneumoniae (NCTC418), and methicillin-resistant S. aureus (COL). The minimal
inhibitory concentration (MIC) was determined by using the broth microdilution method. A colony of
bacteria was picked and grown in a Luria-Bertani (LB, Sigma Aldrich, Buchs, Switzerland) medium
overnight at 37 ◦C. Stock solutions of 1 mg/mL of the samples were prepared in sterilized Milli-Q
water and diluted to the starting concentration of 128 µg/mL in 300 µL Mueller Hinton (MH) medium.
The diluted samples were added to the first well of the 96-well microtiter plate (TPP, untreated,
Faust Laborbedarf, AG, Schaffhausen, Switzerland) and diluted serially by 12 . Bacteria were quantified
by measuring the optical density at 600 nm and diluted to OD600 of 0.022 in MH medium. We used 4µL of
the diluted bacterial solution to inoculate the sample solutions (150 µL) with a final inoculation of about
5 × 105 CFU/mL. The plates were then incubated at 37 ◦C for 18 h. For each assay, sterility (broth only)
and growth control (broth with bacterial inoculum, without antibiotics) were checked with two columns
in the plate. The next day, 15 µL of MTT (1 mg/mL stock solution) (Sigma Aldrich, Buchs, Switzerland)
was added to each well of the plate. The MIC was defined as the lowest concentration of the peptide
dendrimer with a colorless well indicating no bacterial growth.
3.3. Checkerboard Assay
To verify the activity of two drugs in combination, the checkerboard method was used to determine
the MICs for each antibiotic alone and in combination. Both G3KL [37] and a paired small molecule
(propidium iodide, sulfamethoxazole, chloramphenicol, novobiocin, azithromycin, erythromycin,
ciprofloxacin, gentamicin, ampicillin, and trimethoprim) were diluted by 1/2 in a 96 well plate.
Stock solutions of 1 mg/mL of the antibiotics were prepared in sterilized Milli-Q water and diluted to
the starting concentration with 2–4 ×MIC of the corresponding compounds in 300 µL Mueller Hinton
(MH) medium. For propidium iodide, the starting concentration was 1000 µg/mL. For checkerboard
assay testing the combinations of PI with G3KL, PMB, and ciprofloxacin, PI was diluted across
the rows and G3KL, PMB, and ciprofloxacin across the columns. For checkerboard assay testing
the combinations of G3KL with small-molecule antibiotics, G3KL was diluted across the rows and
the small-molecule antibiotics across the columns. We then added 75 µL containing 2× the final
concentration of G3KL, PMB, and ciprofloxacin to each well containing the respective drug (PI and the
small-molecule drugs) to be tested in combination, across the columns and down the rows, resulting in
a checkerboard of 150 µL final volume with the final wells containing only G3KL or the antibiotics.
Similar to broth microdilution, bacteria were quantified by measuring the optical density at 600 nm
and diluted to OD600 of 0.022 in an MH medium. We used 4 µL of the diluted bacterial solution to
inoculate the sample solutions (150 µL) with a final inoculation of about 5 × 105 CFU/mL. The plates
were then incubated at 37 ◦C for 18 h. The next day, 15 µL of MTT (1 mg/mL stock solution) was added
to each well of the plate so that MIC and MICcomb were defined as the lowest concentration of the
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peptide dendrimer and/or antibiotics with a colorless well indicating no bacterial growth. The FIC of
each antibiotic was calculated as follows:
FICA (MICAcomb/MICA) + FICB (MICBcomb/MICB) = ΣFIC = FICindex (FICi).
A synergistic interaction is defined by an FIC index of <0.5, partial synergy is defined by an FIC
index of ≥0.5 and <1, an additive interaction by an FIC index of 1.0, indifferent by an FIC of >1 and <4,
and antagonism is defined by an FIC of ≥4 [43].
3.4. Time-Kill Assay
Time-kill kinetics against K. pneumoniae (NCTC418) were performed on G3KL (32 µg/mL),
vancomycin (32 µg/mL), erythromycin (16 µg/mL), novobiocin (2 µg/mL), G3KL/vancomycin
(32/32 µg/mL), G3KL/trimethoprim (32/16 µg/mL), and G3KL/erythromycin (32/16 µg/mL) and using
2× the concentrations indicated by the checkerboard assay. Untreated bacteria at 1 × 106 CFU/mL were
used as a growth control.
A single colony of K. pneumoniae (NCTC418) was picked and grown overnight with
shaking (180 rpm) in a 5 mL LB medium (Sigma Aldrich, Buchs, Switzerland) at 37 ◦C.
The overnight bacterial culture was diluted to OD600 0.002 (2 × 106 CFU/mL) in fresh MH
(Sigma Aldrich, Buchs, Switzerland) medium. Stock solutions of G3KL and antibiotics (8 mg/mL) were
prepared in sterilized Milli-Q water and diluted to two-times more concentrated than the required
concentration in the fresh MH (Sigma Aldrich, Buchs, Switzerland) medium. G3KL and antibiotic
were pre-mixed when needed. We mixed 100 µL of the adjusted bacteria and 100 µL samples in
a 96-well microtiter plate (TPP, untreated, Corning Incorporated, Kennebunk, ME, USA) and the
time-kill kinetics started at the moment of mixing. Ninety-six-well microtiter plates were incubated
at 37 ◦C under shaking (180 rpm). Bacterial growth was quantified at 0, 0.5, 1, 2, 3, 4, 5, and 6 h,
G3KL/erythromycin (32/16 µg/mL) were also quantified at 7 and 8 h. The quantification was performed
by plating 10-fold dilutions of a sample in sterilized 0.9% NaCl on LB agar plates. LB agar plates were
incubated at 37 ◦C for 10 h and the number of individual colonies was counted at each time-point.
The assay was performed in triplicate.
4. Conclusions
The experiments above showed that the membrane permeabilizing effects of antimicrobial peptide
dendrimer G3KL can be exploited to obtain synergistic effects with other substances. G3KL showed
only weak or no synergy with small-molecule antibiotics in the case of P. aeruginosa, a bacterium
against which the dendrimer is very active, probably because the concentration of G3KL necessary to
permeabilize the membrane is very close to the MIC value. G3KL showed very significant synergistic
effects when tested against K. pneumoniae, against which the dendrimer is inactive when used alone,
revealing that G3KL is capable of permeabilizing the membrane even if it does not show activity.
The effect is particularly striking in combination with vancomycin, erythromycin, or trimethoprim
because these antibiotics are inactive against K. pneumoniae when used alone. However, our synergistic
study showed no effects against MRSA, indicating that G3KL is not only inactive against this
Gram-positive bacterium, but also does not significantly permeabilize its membrane.
Supplementary Materials: The following are available online. Figures S1–S5: Checkerboard microtiter plate
assay testing the combination of G3KL and PMB with PI in P. aeruginosa, E. coli, A. baumannii, and K. pneumoniae.
Figures S6–S9: Checkerboard microtiter plate assay testing the combination of G3KL with small molecule drugs
in P. aeruginosa. Figures S10–S12: Checkerboard microtiter plate assay testing the combination of G3KL with small
molecule drugs in K. pneumoniae. Figures S13–S16: Checkerboard microtiter plate assay testing the combination of
G3KL with small molecule drugs in MRSA. Figure S17: Static time-kill assay of novobiocin at 2 ×MIC (16 µg/mL).
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